Prescription profile of pyridostigmine use in a population of patients with myasthenia gravis

Autor:	Jorge Enrique, Machado-Alba, Luis Felipe, Calvo-Torres, Andrés, Gaviria-Mendoza, César, Augusto MejíA-Vélez
Rok vydání:	2017
Předmět:	Adult Aged 80 and over Male Adolescent Colombia Middle Aged Drug Prescriptions Young Adult Cross-Sectional Studies Myasthenia Gravis Humans Immunologic Factors Drug Therapy Combination Female Cholinesterase Inhibitors Child Aged Pyridostigmine Bromide
Zdroj:	Musclenerve. 56(6)
ISSN:	1097-4598 1041-1046
Popis:	We determined the pyridostigmine prescription pattern in a population of patients with myasthenia gravis (MG). A descriptive cross-sectional study was conducted by using a prescription database of 3.5 million individuals from which patients who had been diagnosed with MG and for whom pyridostigmine had been prescribed were selected. A total of 306 outpatients with MG were found, and 258 were receiving pyridostigmine (mean age 53.0 ± 18.0 years). The calculated prevalence of MG was 86.7 cases per million persons. Monotherapy was used by 53.1% of the patients, prednisolone was used by 21.7%, and 30.2% used other immunomodulators. Medications for other comorbidities were taken by 74.8% of the patients, and 43.4% had prescriptions that could potentially trigger worsening symptoms. Pyridostigmine is being prescribed at doses close to the defined daily doses predominantly as monotherapy. A high proportion of patients were also prescribed a medication that could aggravate their condition, including some that can trigger a myasthenic crisis. Muscle Nerve 56: 1041-1046, 2017.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::a1fa489333ccc0a569ea5f933d7bd3ac https://pubmed.ncbi.nlm.nih.gov/28214292 Zobrazit plný text záznamu Plný text